Andrx Resumes Full Operations Post-Hurricane Wilma
27 October 2005 - 5:36AM
Business Wire
Andrx Corporation (Nasdaq: ADRX) ("Andrx" or "Company") today
announced that it has resumed its pharmaceutical manufacturing
operations following Hurricane Wilma and suffered only minor damage
to its facilities. Anda, Inc. and Valmed Pharmaceutical, Inc.
(VIP), the Company's distribution businesses, with facilities in
Weston, Florida, Grand Island, New York and Columbus, Ohio, have
been in continuous operations throughout the week. Commenting on
its operations, Thomas P. Rice, Andrx Corporation Chief Executive
Officer, said: "Through the dedicated efforts of our employees and
vendors in the wake of Hurricane Wilma, Andrx is manufacturing and
shipping its products." Communications in South Florida continue to
be a challenge. Consequently, Andrx suggests that any
communications to the Company be directed through the Internet or
via telephone at 1-800-331-2632. About Andrx Corporation We are a
pharmaceutical company that: -- develops, manufactures and
commercializes generic versions of controlled-release, niche and
immediate-release pharmaceutical products, including oral
contraceptives; -- distributes pharmaceuticals, primarily generics,
which have been commercialized by others, as well as our own,
primarily to independent pharmacies, pharmacy chains and
physicians' offices; and -- develops and manufactures
pharmaceutical products for other pharmaceutical companies,
including combination products and controlled-release formulations
utilizing our patented technologies and formulation capabilities.
Forward-looking statements (statements which are not historical
facts) in this release are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
For this purpose, any statements contained herein or which are
otherwise made by or on behalf of the Company that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the generality of the foregoing, words
such as "may," "will," "to," "plan," "expect," "believe,"
"anticipate," "intend," "could," "would," "estimate," or "continue"
or the negative other variations thereof or comparable terminology
are intended to identify forward-looking statements. Investors are
cautioned that all forward-looking statements involve risk and
uncertainties, including but not limited to: business interruption
due to hurricanes or other events outside of the Company's control,
what sanctions, if any, FDA may seek, following its decision to
place Andrx in OAI (Official Action Indicated) status, and when the
"hold" on the Company's ANDA approvals will be lifted, the
Company's dependence on a relatively small number of products,
licensing revenues, the timing and outcome of litigation and future
product launches, government regulation, competition, manufacturing
capacities, safety issues, output and quality processes, recent
management appointments and changes and the potential loss of
senior management and other key personnel. We are also subject to
other risks detailed herein or detailed from time to time in our
Annual Report on Form 10-K for the year ended December 31, 2004, or
in our other SEC filings. Subsequent written and oral
forward-looking statements attributable to us or to persons acting
on our behalf are expressly qualified in their entirety by the
cautionary statements set forth in our Annual Report on Form 10-K
for the year ended December 31, 2004, and in our other SEC filings.
This release and additional information about Andrx Corporation are
also available on the Internet at: http://www.andrx.com.
Andrx (NASDAQ:ADRX)
Historical Stock Chart
From May 2024 to Jun 2024
Andrx (NASDAQ:ADRX)
Historical Stock Chart
From Jun 2023 to Jun 2024